Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Eir
  6. /
  7. Forest Pharmaceuticals, Inc
EIR
•Forest Pharmaceuticals, Inc•September 22, 2015

Forest Pharmaceuticals, Inc – FDA EIR, Sep 22, 2015

Record Details

An FDA inspection was conducted at Forest Pharmaceuticals Inc. in Cincinnati, OH, on September 22, 2015. This focused inspection followed up on three significant product complaints submitted to the FDA, scrutinizing the company's complaint handling processes. The complaints involved Teflaro for injection, where a patient repeatedly observed dark particulate matter, and two separate Amour Thyroid complaints detailing patient adverse events, including severe reactions and side effects possibly related to product use following corporate acquisitions. Crucially, no new deficiencies were identified that merited an FDA-483 (Inspectional Observations) form. However, the inspection revealed that several of these critical complaints remained unresolved. For the Teflaro particulate complaint, the firm was still awaiting a product sample to finalize its investigation into potential product degradation. Similarly, for one Amour Thyroid adverse event, the investigation remained open as the company sought a sample from the complainant. The other Amour Thyroid complaint lacked sufficient information, like a lot number or sample, to conduct a full investigation. Operating under the regulatory framework for pharmaceutical complaint management, the FDA investigators reiterated the requirement for Forest Pharmaceuticals to meticulously review and handle all complaints and adverse events in accordance with established regulations. Although no formal corrective actions were mandated through an FDA-483, company management pledged to undertake further follow-up with the affected complainants to address the outstanding issues.

Company
Forest Pharmaceuticals, Inc
Inspection date
September 22, 2015
Product type
drugs
Office
Cincinnati District Office
People
  • Bailey A. Uetrecht (issuing_officer)
  • Douglas W. Yelton (recipient)
  • Warren G. Meinschein Jr. (company_representative)
  • Trever L. Dalzell (company_representative)
  • Serena D. Brady (company_representative)
View Company Profile

ID · 3860e3d8-be85-4852-9aaa-b41797699e0e

Other documents for Forest Pharmaceuticals, Inc
  • EIR - 2016-05-20May 20, 2016

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Forest Pharmaceuticals, Inc
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.